Home » Regions » Global News » Retroscreen Virology purchases ALPHADAS

Retroscreen Virology purchases ALPHADAS

Wednesday, July 31, 2013

Retroscreen Virology Group, a virology healthcare company, has purchased the ALPHADAS clinical trials software suite to accelerate and reduce the cost of bringing anti-viral drugs, diagnostics and vaccines to market.

ALPHADAS is an eSource clinical research and early phase trials system that is mobile, schedule-driven and provides real-time bedside or station-based direct data capture that eliminates paper-based data.

ALPHADAS will increase efficiencies and quality through direct data captured from Retroscreen instrumentation and manage and monitor samples through the study lifecycle while offering real-time data review.

Retroscreen conducts the Human Viral Challenge Model in a controlled quarantine environment, providing a cost-effective study design which accelerates the selection of a safe and effective dose, and dosing regimen, for a new antiviral drug or vaccine. ALPHADAS will streamline clinical trial research processes across multiple sites.

It also will be used for accelerated recruitment, staff resourcing and site management operations.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!